Anti-heparanase activity of ultra-low-molecular-weight heparin produced by physicochemical depolymerization
- 1 January 2016
- journal article
- Published by Elsevier in Carbohydrate Polymers
- Vol. 135, 316-323
Abstract
No abstract availableKeywords
Funding Information
- Ligue Contre le Cancer of Charente-Maritime
- Ligue Contre le Cancer of Charente-Maritime
- PRES
This publication has 47 references indexed in Scilit:
- Profiling glycol-split heparins by high-performance liquid chromatography/mass spectrometry analysis of their heparinase-generated oligosaccharidesAnalytical Biochemistry, 2013
- Anti-angiogenesis therapy in cancer: Current challenges and future perspectivesCancer Letters, 2012
- SST0001, a Chemically Modified Heparin, Inhibits Myeloma Growth and Angiogenesis via Disruption of the Heparanase/Syndecan-1 AxisClinical Cancer Research, 2011
- Unraveling the Specificity of Heparanase Utilizing Synthetic SubstratesJournal of Biological Chemistry, 2010
- The potential benefits of low-molecular-weight heparins in cancer patientsJournal of Hematology & Oncology, 2010
- PI-88: a novel inhibitor of angiogenesisExpert Opinion on Investigational Drugs, 2008
- Non-Anticoagulant Heparins and Inhibition of CancerPathophysiology of Haemostasis and Thrombosis, 2007
- Pro-angiogenic cytokines and their role in tumor angiogenesisCancer and Metastasis Reviews, 2006
- The anticoagulant activity of heparin: Measurement and relationship to chemical structureJournal of Pharmaceutical and Biomedical Analysis, 1989
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971